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Abstract
Background: PDLIM2 is essential for the termination of the inflammatory transcription factors NF-κB and STAT but
is dispensable for the development of immune cells and immune tissues/organs. Currently, it remains unknown
whether and how PDLIM2 is involved in physiologic and pathogenic processes.
Results: Here we report that naive PDLIM2 deficient CD4
+ T cells were prone to differentiate into Th1 and Th17
cells. PDLIM2 deficiency, however, had no obvious effect on lineage commitment towards Th2 or Treg cells.
Notably, PDLIM2 deficient mice exhibited increased susceptibility to experimental autoimmune encephalitis (EAE), a
Th1 and/or Th17 cell-mediated inflammatory disease model of multiple sclerosis (MS). Mechanistic studies further
indicate that PDLIM2 was required for restricting expression of Th1 and Th17 cytokines, which was in accordance
with the role of PDLIM2 in the termination of NF-κB and STAT activation.
Conclusion: These findings suggest that PDLIM2 is a key modulator of T-cell-mediated immune responses that
may be targeted for the therapy of human autoimmune diseases.
Background
CD4
+ T helper (Th) cells play a central role in orchestrat-
ing immune responses to diverse microbial pathogens [1].
Upon activation by antigens, naive CD4
+ Tcells differenti-
ate into specialized effector T (Teff) cells (Th1, Th2, or
Th17), which secrete different patterns of cytokines and
perform different functions [1]. Th1 cells produce inter-
feron-γ (IFN-γ) and tumor necrosis factor-α (TNF-α)a n d
initiate cellular immune responses against intracellular
pathogens. Th2 cells generate interleukin-4 (IL-4), IL-5
and IL-13 and promote humoral responses against extra-
cellular parasites. Th17 cells make IL-17, IL-21 and IL-22
and confer immunity against extracellular bacteria and
fungi. Moreover, activated CD4
+ T cells also differentiate
into regulatory T (Treg) cells, which express transforming
growth factor-β (TGF-β), IL-10 and IL-35 and suppress
the functions of Teff cells, thereby keeping immune
responses in check.
Imbalance of Th cell differentiation and subsequent cyto-
kine dysregulation is implicated in inflammatory and
autoimmune diseases [2]. In particular, Th1 and Th17 cells
and their signature cytokines IFN-γ and IL-17 have been
shown to play a critical role in the development of autoim-
mune responses in many autoimmune diseases, including
multiple sclerosis (MS) and rheumatoid arthritis [2-4]. In
accordance with the significance of Th cell differentiation
in animal physiology and pathology, the molecular mechan-
isms underlying this important process have been exten-
sively investigated. In this regard, the signal transducers and
activators of transcription (STAT) proteins are well known
for their essential roles in transmitting cytokine-mediated
signals and specifying Th cell differentiation [1,2]. In gen-
eral, STAT4 is activated mainly by IL-12 and type I IFNs,
and it functions predominantly in promoting Th1 cell dif-
ferentiation. STAT6 is activated in response to IL-4 and
functions as the molecular switch for initiation of the Th2
cell differentiation program. Soon after activation by IL-6,
STAT3 triggers Th17 commitment. On the other hand, IL-
2-activated STAT5 facilitates Treg cell differentiation. Simi-
lar to STAT proteins, the NF-κB transcription factors, par-
ticularly the prototypical member RelA (also known as
p65), are also master regulators/activators of immune
responses and inflammation in both healthy and disease
[5,6]. The signaling pathways leading to activation of STAT
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However, it still remains largely unknown how activated
STAT and NF-κB are terminated for proper Th cell differ-
entiation and immune responses and how STAT and NF-
κB are deregulated in autoimmune diseases.
Previous studies show that PDLIM2, a ubiquitously
expressed PDZ-LIM domain-containing protein with
high expression in lymphoid tissues and cells including
T lymphocytes, is required for the termination of STAT
and NF-κB activation [9,10]. More recent studies suggest
that PDLIM2 may function as a tumor suppressor
[11-15]. Mechanistic studies indicate that PDLIM2 se-
lectively promotes ubiquitination and proteasomal deg-
radation of nuclear (activated) STAT4 and RelA proteins
[9-12]. However, whether and how PDLIM2 is involved
in Th cell differentiation remain unknown. In particular,
mouse genetic studies reveal that PDLIM2 is not
required for the development of immune cells and im-
mune tissues/organs [9]. Additionally, it remains un-
known whether PDLIM2 is involved in the pathogenesis
of inflammatory and autoimmune diseases.
Results and discussion
PDLIM2 deficiency in CD4
+ th cells enhances Th1 and
Th17 cell differentiation but has no obvious effect on Th2
and Treg cell differentiation
To test whether PDLIM2 is involved in Th cell differenti-
ation, naive CD4
+ Th cells were isolated from spleens of
PDLIM2
−/− and PDLIM2
+/+ mice and stimulated by anti-
CD3/anti-CD28 under Th1, Th2, Th17 or Treg polarizing
condition. Loss of PDLIM2 did not affect the differentiation
of Th cells to Th2 or Treg, as evidenced by similar numbers
of Th2 and Treg cells produced from naive PDLIM2
−/− and
PDLIM2
+/+ CD4
+ Th cells (Figure 1). In contrast, much
more Th1 and Th17 cells were generated from naive
PDLIM2
−/− CD4
+ Th cells compared to PDLIM2
+/+ cells.
These data suggest that PDLIM2 plays a specific role in
restricting Th1 and Th17 cell differentiation.
Mice deficient in PDLIM2 show increased susceptibility to
EAE
Given the causative role of Th1 and Th17 cells in auto-
immune diseases such as MS [2-4], we proposed that
through restriction of Th1 and Th17 cell differentiation,
PDLIM2 is involved in autoimmune disease suppression.
To test this hypothesis and to further characterize the
in vivo role of PDLIM2 in regulating Th1 and Th17 cell
differentiation, we examined the susceptibility of
PDLIM2
−/− and PDLIM2
+/+ mice to EAE, a well-defined
model of MS [16]. In agreement with previous studies
[17], 20% of PDLIM2
+/+ mice developed acute EAE with a
2.8 mean peak clinical score and a mean disease onset of
day 17.3±2.5) of post-immunization with the encephalito-
genic PLP180-199 epitope (Figure 2). Remarkably, over 50%
of PDLIM2
−/− mice developed EAE with an earlier disease
onset (13.1±1.9 day of post-immunization) and a more
γ
Figure 1 Enhanced Th1 and Th17 differentiation of PDLIM2 deficient CD4
+ Th cells. Naive CD4
+ Th cells isolated from PDLIM2
+/+ (WT) or
PDLIM2
−/− (KO) mice were stimulated for 72 hours with anti-CD3/anti-CD28 under Th1, Th2, Th17 or Treg polarizing condition, followed by
intracellular cytokine staining and flow cytometry. The data are representative of at least three independent experiments with similar results.
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ease course. These data clearly indicate that PDLIM2 plays
a critical role in suppressing EAE.
PDLIM2 expression in CD4
+ T cells is critical for EAE
suppression
To determine whether the effect of PDLIM2 deficiency
on EAE is CD4
+ T-cell specific, we performed adoptive
CD4
+ T-cell transfer studies using SCID mice as
receipts, which lack CD4
+ T cells. Although the disease
severity in adoptive transfer recipients was less robust
overall than that observed in immunized mice, the dif-
ference of EAE induction in the receipts of PDLIM2
+/+
versus PDLIM2
−/− T cells was still significant and similar
to that observed in PDLIM2
+/+ and PDLIM2
−/− mice
(Figure 3). These data suggest that the observed increase
in EAE severity in PDLIM2
−/− mice is due to the defi-
ciency of PDLIM2 in CD4
+ T cells.
PDLIM2 deficiency leads to increased STAT and NF-κB
activation and augmented production of Th1 and Th17
cytokines
As EAE is mediated by Th1 and/or Th17 cells [3], we
examined whether the exacerbated EAE in PDLIM2
−/−
mice is associated with increased Th1 and Th17 cell dif-
ferentiation in the mice. As expected, the expression
levels of Th1 cytokines (IFN-γ and TNF-α) and Th17
cytokines (IL-17, IL-21 and IL-22) were significantly
higher in PLP180-199-stimulated PDLIM2
−/− mice com-
pared to the PDLIM2
+/+ mice under the same treatment
(Figure 4A). On the other hand, the expression levels of
Th2 cytokines (IL-4, IL-5 and IL-13) and Treg cytokines
(TGF-β and IL-10) were comparable in the PLP180-199-
treated PDLIM2
+/+ or PDLIM2
−/− mice. These data
Figure 2 Increased susceptibility to EAE in PDLIM2 deficient mice. A) Incidence, B) disease progression, C) severity and D) onset of EAE in
PDLIM2
+/+ and PDLIM2
−/− mice (n=15). Mice were immunized with PLP180–199 peptide and monitored daily for EAE disease symptoms. The p
values between the PDLIM2
+/+ (WT) and PDLIM2
−/− (KO) groups are at least smaller than 0.05 by two tailed t-test.
Figure 3 Increased severity of adoptive transfer EAE in
recipients of PDLIM2 deficient CD4
+ T cells. CD4
+ T cells were
isolated from PDLIM2
+/+ and PDLIM2
−/− mice immunized with
PLP180–199 peptide and transferred i.v. into SCID recipients (n=20).
One day after the cell transfer, recipient mice also received an
injection of pertussis. Mice were then monitored for the symptoms
of EAE as described in Figure 2.
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Th1 and Th17 cell differentiation.
To determine the molecular mechanisms by which
PDLIM2 controls Th1 and Th17 cell differentiation for
EAE suppression, we examined the expression levels of
STAT4 and RelA proteins in the nucleus (activation
marker) of CD4
+ T cells isolated from PLP180-199-treated
PDLIM2
+/+ mice or PDLIM2
−/− mice. In this regard, it is
known that PDLIM2 promotes proteasomal degradation
of nuclear STAT4 and RelA proteins [9-12]. More im-
portantly, STAT4 is a determinative factor of Th1 cell
differentiation and also participates in Th17 cell differ-
entiation [18,19]. On the other hand, RelA regulates
transcriptional expression of numerous cytokines that
are involved in Th1 and Th17 cell differentiation and
EAE pathogenesis such as IFNs, TNF-α and IL-6 [6]. In
fact, a recent study has already linked RelA to Th17 re-
sponse [20]. Given the critical role of STAT3 in Th17
cell differentiation [21], we also included STAT3 in our
studies. As shown in Figure 4B, significantly higher levels
of STAT3, STAT4 and RelA proteins were detected in
PLP180-199-treated T cells from PDLIM2
−/− mice as com-
pared to those from PDLIM2
+/+ mice. The increased nu-
clear expression/activation of STAT3, STAT4 and RelA
should be the driving force but not the consequences of
enhanced Th1 and Th17 cell differentiation nor the out-
come of exacerbated EAE in PDLIM2
−/− mice, because an
obvious increase in the nuclear expression of STAT3,
STAT4 and RelA proteins was already detected within 30
minutes after cell stimulation (Figure 4C). Our biochem-
ical studies indicated that similar to its role in the negative
regulation of STAT4 and RelA (9–12), PDLIM2 bound to
nuclear STAT3 for ubiquitination and proteasomal deg-
radation (Figure 5). During the preparation of our manu-
script, another group also showed that PDLIM2 targets
STAT3 for degradation [22]. These data together suggest
that PDLIM2 negatively regulates activation of STAT3/4
and RelA and therefore restricts Th1 and Th17 cell differ-
entiation and prevents EAE development.
The STAT and NF-κB transcription factors play critical
roles at multiple levels of the immune system in both
health and disease, including the autoimmune inflamma-
tory response [1-6]. The mechanisms of how STAT and
NF-κB are activated to drive immune responses have
been well defined [7,8]. However, how those key immune
regulators are negatively regulated during Th cell differ-
entiation and how they become constitutively and per-
sistently activated in autoimmune diseases remain
largely unknown. The data presented in this study de-
monstrate that PDLIM2 functions as an essential
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Figure 4 Enhanced nuclear expression of STAT3/4 and RelA proteins and augmented production of Th1 and Th17 cytokines in PDLIM2
deficient Teff cells. Splenic T cells from day 10 PLP180–199-immunized PDLIM2
+/+ (WT) or PDLIM2
−/− (KO) mice were subjected to QRT-PCR to
detect the relative expression levels of the indicated cytokines genes (A) or ELISA to detect the nuclear expression levels of STAT3, STAT4 and
RelA (B). The expression levels of the indicated genes and proteins were represented as fold induction relative to their WT controls. C) Naive
PDLIM2
−/− or PDLIM2
+/+ CD4
+ Th cells were stimulated for the indicated time points with anti-CD3/anti-CD28 under Th1 or Th17 polarizing
condition, followed by ELISA to detect the nuclear expression levels of STAT3 (in response to Th17 stimulation), STAT4 and RelA (in response to
Th1 stimulation). In A-C, n=3, *, p<0.03; **, p<0.003 by two tailed t-test.
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no apparent effect on Th2 and Treg cell differentiation.
Interestingly, the novel function of PDLIM2 in Th cell
differentiation is most likely through restricting activa-
tion of STAT3/4 and RelA. These data identify STAT3
as a new target of PDLIM2 for ubiquitin-mediated pro-
teasomal degradation and also suggest a new mechanism
of RelA in immune responses involving regulation of
Th1 and Th17 cell differentiation. These findings pro-
vide important insights into molecular mechanisms
underlying immune responses and suggest PDLIM2 as
a new therapeutic target for inflammatory and auto-
immune diseases.
Methods
Mice
PDLIM2
−/− mice were backcrossed with BALB/c mice at
least 10 generations for pure BALB/c background.
PDLIM2
−/− BALB/c mice and control PDLIM2
+/+
BALB/c mice were housed under specific pathogen-free
conditions at the Hillman Cancer Center of the Univer-
sity of Pittsburgh Cancer Institute. Animal experiments
were approved by the Institutional Animal Care and Use
Committee (IACUC) of the University of Pittsburgh.
Experimental autoimmune encephalitis (EAE) induction
and clinical scoring
Six to eight-week-old female mice were immunized sub-
cutaneously with PLP180–199 peptide (200 μg/mouse,
Genemed Synthesis Inc.) emulsified in CFA containing
Mycobacterium tuberculosis H37Ra (500 μg/mouse, BD
Diagnostics). Mice also received 300 ng of pertussis
toxin (List Biological Laboratories) intraperitoneally (i.p.)
at the time of immunization and 48 hours later. Mice
were monitored daily for clinical signs of paralysis and
scored as follows: 0, no clinical signs; 1, limp tail; 2,
weak/partially paralyzed hind legs; 3, limp tail and
complete paralysis of hind legs; 4, complete hind and
partial front leg paralysis; 5, complete paralysis or mori-
bund state.
Adoptive transfer of CD4
+ T cells for induction of EAE
Lymph nodes and spleens were harvested from PDLIM2
+/+
or PDLIM2
−/− mice immunized with PLP180–199,a n d
lymph node cells and splenocytes were cultured in vitro
C
Figure 5 Ubiquitination and proteasomal degradation of STAT3 by PDLIM2. A) Physical interaction between PDLIM2 and STAT3. Nuclear
extracts of 293 cells transfected with HA-STAT3 alone or together with Myc-PDLIM2 were subjected to immunoprecipitation (IP) using Myc
antibody and immunoblotting (IB) using HA antibody. The expression levels of HA-STAT3 and Myc-PDLIM2 were examined by IB. B) Polyubiquitination
of STAT3 by PDLIM2. 293 cells were transfected with HA-STAT3 plus Flag-ubiquitin in the presence or absence of Myc-PDLIM2, followed by nuclear
fractionation. The nuclear extracts were subjected to IP using HA antibody and IB using Flag antibody. The expression levels of HA-STAT3 and
Myc-PDLIM2 were examined by IB. C) Proteasomal degradation of STAT3 by PDLIM2. 293 cells transfected with HA-STAT3 alone or together with
Myc-PDLIM2 were cycloheximide (CHX)-chased for the indicated time, followed by nuclear extractions and IB using HA or Myc antibody. In lanes 3 and
6, the cells were chased in the presence of 10 μMM G 1 3 2 .
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+ Tc el l sw er e
then positively selected by MACS separation using mag-
netic CD4
+ microbeads (Miltenyi Biotec, Auburn, CA) per
manufacturer’si n s t r u c t i o n s .5x1 0
6 CD4
+ T cells were
adoptively transferred by intravenous (i.v.) injection into
SCID recipients on day 0. On day 2, mice received an i.p.
injection of pertussis toxin (250 ng), and mice were then
monitored for symptoms of disease.
CD4
+ th cell purification and in vitro differentiation
Naive CD4
+CD25
- T cells were first isolated from spleno-
cytes using CD4
+ T-cell Isolation Kit (Miltenyi Biotec.) and
then sorted out by FACSAria (BD Biosciences). Purified
naive CD4
+CD25
- Tcells were stimulated with plate-bound
anti-CD3 and anti-CD28 (1 μg/ml) under Th1 (mIL-2
10 ng/ml, mIL-12 10 ng/ml),T h 2( I L - 41 0n g / m l ,a n t i -
IFNγ 10 μg/ml), Th17 (anti-IFNγ 10 μg/ml, anti-IL-4
10 μg/ml, hIL-6 10 ng/ml, hTGF-β 10 ng/ml) or Treg
(hTGFβ,1 0n g / m l ,a n t i - I L - 41 0μg/ml, anti-IFNγ 10 μg/ml)
(BD Biosciences or eBioscience) polarizing condition. 72
hours after the initial stimulation, the cells were subjected
to intracellular cytokine staining (ICS)/flow cytometry ana-
lysis and quantitative real-time RT-PCR (QRT-PCR) as
described below.
ICS and flow cytometry
T cells were stimulated for 5 hours with PMA (50 ng/ml)
and ionomycin (500 ng/ml) in the presence of intracellular
transport inhibitor monesin (10 μg/ml; Sigma), followed
by fixation with paraformaldehyde (2%) and permeabliza-
tion with saponin (0.5%). Cells were then treated with
anti-IFN-γ-FITC (XMG1.2), anti-IL-4-PE (11B11), anti-
IL-17-PE (TC11-18 H10), and anti-Foxp3–FITC (FJK-
16 s) (BD Biosciences or eBioscience). Data were acquired
using FACSCalibur (BD Biosciences) and analyzed using
CellQuest software (Becton Dickinson) as described previ-
ously [23].
QRT-PCR
Total RNA was prepared with TRIZOL reagent and
cDNA was generated with SuperScript II reverse tran-
scriptase (Invitrogen), followed by real-time PCR assays
using Fast start SYBR Green reagents (Roche) as des-
cribed [24,25]. The gene-specific primer pairs were:
IFN-γ,5 ’-TTCTTCAGCAACAGCAAGGCGAA-3’ and
5’-TGAATGCTTGGCGCTGGACCTG-3’; TNF-α,5 ’-G
ATGAGAAGTTCCCAAATGGC-3’ and 5’-ACTTGGT
GGTTTGCTACGACG-3’; TGF-β,5 ’-TGACGTCACT
GGAGTTGTACGG-3’ and 5’-GGTTCATGTCATGGAT
GGTGC-3’; IL-4, 5’-AGGGACGCCATGCACGGAGAT-
3’ and 5’-GCGAAGCACCTTGGAAGCCCTAC-3’; IL-5,
5’-AGCACAGTGGTGAAAGAGACCTT-3’ and 5’-TCC
AATGCATAGCTGGTGATTT-3’; IL-10, 5’-AGCTGAA
GACCCTCAGGATGCG-3’ and 5’- TCATTCATGGCC
TTGTAGACACCTTG-3’; IL-13, 5’-GGCTCTTGCTTG
CCTTGGTG-3’ and 5’-TCCATACCATGCTGCCGTT
G-3’; IL-17, 5’-CTCAGACTACCTCAACCGTTC-3’ and
5’-TGAGCTTCCCAGATCACAGAG-3’; IL-21, 5’-ATCC
TGAACTTCTATCAGCTCCAC-3’ and 5’-GCATTTAG
CTATGTGCTTCTGTTTC-3’; IL-22, 5’-TCCGAGGAG
TCAGTGCTAAA-3’ and 5’-AGAACGTCTTCCAGGG
TGAA-3’; β-actin, 5′-ACCCGCGAGCACAGCTTCTT
TG-3’ and 5’-CTTTGCACATGCCGGAGCCGTTG-3’.
Expression levels of each gene were normalized to that
of β-actin.
Enzyme-linked immunosorbent assay (ELISA)
Cell nuclear fractions were prepared and added to 96-well
plate precoated with anti-RelA, anti-STAT3 or anti-
STAT4. After overnight incubation at 4 °C, plates were
washed extensively with PBS containing 0.1% Tween 20
(PBST), and horseradish peroxidase-conjugated secondary
antibodies were added and incubated for 1 hour at room
temperature. After extensive wash with PBST, a colorimet-
ric substrate 2’2-azinobis(3-ethylenzthiazoline-6-sulfonic
acid) (ABTS) was added and incubated for 15 minutes.
The reaction was stopped by addition of 100 μL1 %s o -
dium dodecyl sulfate (SDS). The optical density at 405 nm
(OD405) was measured with an automated plate spectro-
photometer (Thermo Lab Systems).
Immunoblotting (IB) and immunoprecipitation (IP) assays
Nuclear extracts were subjected to SDS-PAGE and IB,
or IP using the indicated antibodies before SDS-PAGE
and IB as described before [26,27].
In vivo ubiquitin conjugation assay
Cytoplasmic and nuclear extracts were prepared from
HTLV-I-transformed T cells or 293 cells transfected with
HA-STAT3 together with Flag-tagged ubiquitin in the
presence or absence of Myc-PDLIM2, immediately fol-
lowed by IP using anti-HA. The ubiquitin-conjugated
STAT3 pulled down by IP was detected by IB using anti-
Flag [28].
Protein stability assay
Cells were treated with 10 μM CHX, followed by chase
of the indicated time period in the presence or absence
of MG132, and IB to detect the indicated proteins [29].
Statistical analysis
Data were reported as mean±standard deviation (SD).
The Student’st test (two tailed) was used to assess signifi-
cance of differences between two groups, and p values
≤0.05 and 0.01 were considered statistically significant
and highly statistically significant, respectively.
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